NHS patients in Scotland with haemophilia A are set to get access to Roche and Chugai’s prophylactic injection Hemlibra after officials said it was cost-effective.
Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note
Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8 billion deal, ahead of a regulatory deadline later today in the US.
There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising early data from Roche’s mosunetuzumab proved to be one of the major ta